Scientific American September 24, 2021
Andrea Gawrylewski

Medicine accomplished a huge feat at the start of 2020, when researchers produced the first mRNA vaccine to protect humans from SARS-CoV-2 infection. It was certainly not new technology—the vaccine platform had been under development for more than a decade and tested against multiple diseases, from flu to rabies. It represents our rapidly advancing understanding of how the body manufactures proteins, the molecules that are coded for by our genes. The potential to manipulate the very blueprints that our cells use to build the molecules and cells at the heart of disease is undoubtedly a game changer. Beyond vaccines, researchers have been devising treatments for cancer, lymphoma, AIDS, cystic fibrosis, and more, aided by new gene-editing technology,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Gilead bets on Xilio cancer drug as biotech restructures
Pfizer shifts creative to Publicis in latest marketing move
Boundless Bio’s ‘BOLD’ IPO Reels In $100M for a New Kind of Cancer Drug
Joseph La Barge On The Challenges Of Advancing Gene Therapy, Finding The Right Support
Exact Sciences' posts positive data for its capsule-on-a-string test for esophageal cancer

Share This Article